tradingkey.logo
tradingkey.logo
検索

Nexalin Technology Inc

NXL
ウォッチリストに追加
0.361USD
-0.019-5.00%
終値 07/02, 13:00ET15分遅れの株価
7.43M時価総額
損失額直近12ヶ月PER

詳細情報 Nexalin Technology Inc 企業名

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Incの企業情報

企業コードNXL
会社名Nexalin Technology Inc
上場日Sep 16, 2022
最高経営責任者「CEO」White (Mark)
従業員数6
証券種類Ordinary Share
決算期末Sep 16
本社所在地1776 Yorktown
都市HOUSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号77056
電話番号18322600222
ウェブサイトhttps://nexalin.com
企業コードNXL
上場日Sep 16, 2022
最高経営責任者「CEO」White (Mark)

Nexalin Technology Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

よくある質問

Nexalin Technology Incの上位5名の株主は誰ですか?

Nexalin Technology Incの上位5名の株主は以下のとおりです。Ms. Marilyn Elson

Nexalin Technology Inc(NXL)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Nexalin Technology Incの株式を保有している機関は43社あり、保有株式の総市場価値は約1.43Mで、全体の6.94%を占めています。2025Q4と比較して、機関の持ち株は524945.00増加しています。

Nexalin Technology Incの最大の収益源は何ですか?

2026Q1において、Device Sales部門がNexalin Technology Incにとって最大の収益を生み出しており、その金額は136.00Kで、全収益の45.09%を占めています。